0001104659-23-068102.txt : 20230605 0001104659-23-068102.hdr.sgml : 20230605 20230605170751 ACCESSION NUMBER: 0001104659-23-068102 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230605 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230605 DATE AS OF CHANGE: 20230605 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMEDISYS INC CENTRAL INDEX KEY: 0000896262 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082] IRS NUMBER: 113131700 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-24260 FILM NUMBER: 23993658 BUSINESS ADDRESS: STREET 1: 3854 AMERICAN WAY STREET 2: SUITE A CITY: BATON ROUGE STATE: LA ZIP: 70816 BUSINESS PHONE: 2252922031 MAIL ADDRESS: STREET 1: 3854 AMERICAN WAY STREET 2: SUITE A CITY: BATON ROUGE STATE: LA ZIP: 70816 FORMER COMPANY: FORMER CONFORMED NAME: ANALYTICAL NURSING MANAGEMENT CORP DATE OF NAME CHANGE: 19940819 FORMER COMPANY: FORMER CONFORMED NAME: M&N CAPITAL CORP DATE OF NAME CHANGE: 19930125 8-K 1 tm2317787d1_8k.htm FORM 8-K
0000896262 false 0000896262 2023-06-05 2023-06-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 5, 2023

 

Commission File Number: 0-24260

 

 

 

 

 

 

Amedisys, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware 11-3131700
(State or other jurisdiction
of incorporation)		 (IRS Employer
Identification No.)

 

3854 American Way, Suite A, Baton Rouge, LA 70816

(Address and zip code of principal executive offices)

 

(225) 292-2031 or (800) 467-2662

(Registrant's telephone number, including area code) 

 

Not Applicable
(Former name or former address, if changed since last report) 

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

x Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
x Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each Class Trading Symbol(s) Name of Each Exchange
on Which Registered
Common Stock. $0.001 par value per share AMED The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 7.01.Regulation FD Disclosure

 

On June 5, 2023, Amedisys, Inc., a Delaware corporation ("Amedisys") issued a press release announcing the receipt of an unsolicited proposal from Optum, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information contained under this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act except as may be expressly set forth by specific reference in such filing.

 

No Offer or Solicitation

 

This communication relates to the proposed merger of Uintah Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Option Care Health, Inc., a Delaware corporation ("OPCH") ("Merger Sub") with and into Amedisys (the "proposed transaction"), with Amedisys surviving the Merger as a wholly-owned subsidiary of OPCH, as contemplated by and subject to the satisfaction or waiver of specified conditions in, the Agreement and Plan of Merger by and among Amedisys, OPCH and Merger Sub (the "Merger Agreement"). This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933.

 

Additional Information and Where to Find It

 

In connection with the proposed transaction, OPCH and Amedisys have filed relevant materials with the United States Securities and Exchange Commission (the "SEC"), including an OPCH registration statement on Form S-4 that includes a preliminary joint proxy statement of OPCH and Amedisys that also constitutes a prospectus of OPCH. The registration statement has not been declared effective by the SEC. A definitive joint proxy statement/prospectus will be mailed to stockholders of OPCH and Amedisys after the registration statement has been declared effective by the SEC. INVESTORS AND SECURITY HOLDERS OF OPCH AND AMEDISYS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS THAT HAVE BEEN OR WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders may obtain free copies of the registration statement and the joint proxy statement/prospectus and other documents filed with the SEC by OPCH or Amedisys through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by OPCH are available free of charge on OPCH's internet website at https://investors.optioncarehealth.com or by contacting OPCH's investor relations department at investor.relations@optioncare.com. Copies of the documents filed with the SEC by Amedisys are available free of charge on Amedisys' internet website at https://investors.amedisys.com or by contacting Amedisys' investor relations department at IR@amedisys.com.

 

Certain Information Regarding Participants

 

OPCH, Amedisys and their respective directors and executive officers may be considered participants in the solicitation of proxies in connection with the proposed transaction.  Information about the directors and executive officers of OPCH is set forth in its proxy statement for its 2023 annual meeting of stockholders, which was filed with the SEC on April 7, 2023. Information about the directors and executive officers of Amedisys is set forth in its proxy statement for its 2023 annual meeting of stockholders, which was filed with the SEC on April 27, 2023. Other information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, is contained in the joint proxy statement/prospectus and other relevant materials filed with the SEC regarding the proposed transaction. You may obtain these documents free of charge through the website maintained by the SEC at http://www.sec.gov and from the investor relations departments at OPCH or Amedisys as described above.

 

2

 

Cautionary Statement Regarding Forward-Looking Statements

 

This communication may contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "believe," "project," "estimate," "expect," "may," "should," "will" and similar references to future periods. Examples of forward-looking statements include the closing date for the proposed transaction.

 

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management's current beliefs, expectations and assumptions regarding the future of OPCH's and Amedisys's business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of OPCH's and Amedisys's control. OPCH's, Amedisys's and the combined company's actual results and financial condition may differ materially from those indicated in the forward-looking statements as a result of various factors. These factors include, among other things, (1) the termination of or occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement or the inability to complete the proposed transaction on the anticipated terms and timetable, (2) the inability to complete the proposed transaction due to the failure to obtain approval of the stockholders of OPCH or Amedisys or to satisfy any other condition to closing in a timely manner or at all, or the risk that a regulatory approval that may be required for the proposed transaction is delayed, is not obtained or is obtained subject to conditions that are not anticipated, (3) the ability to recognize the anticipated benefits of the proposed transaction, which may be affected by, among other things, the ability of the combined company to maintain relationships with its patients, payers and providers and retain its management and key employees, (4) the ability of the combined company to achieve the synergies contemplated by the proposed transaction or such synergies taking longer to realize than expected, (5) costs related to the proposed transaction, (6) the ability of the combined company to execute successfully its strategic plans, (7) the ability of the combined company to promptly and effectively integrate the OPCH and Amedisys businesses and (8) the diversion of management's time and attention from ordinary course business operations to completion of the proposed transaction and integration matters. The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included elsewhere. Additional information concerning risks, uncertainties and assumptions can be found in OPCH's and Amedisys's respective filings with the SEC, including the risk factors discussed in OPCH's and Amedisys's most recent Annual Reports on Form 10-K, as updated by their Quarterly Reports on Form 10-Q and future filings with the SEC, as well as the risk factors in the joint proxy statement/prospectus.

 

Any forward-looking statement made in this communication is based only on information currently available to OPCH and Amedisys and speaks only as of the date on which it is made. OPCH and Amedisys undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. You are cautioned not to rely on OPCH's and Amedisys's forward-looking statements.

 

3

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No. 

  

Description 

99.1   Joint Press Release, dated as of June 5, 2023, issued by Option Care Health, Inc. and Amedisys, Inc.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

4

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  AMEDISYS, INC.
   
Dated: June 5, 2023 By: /s/  Richard Ashworth
    Name:  Richard Ashworth
    Title: President and Chief Executive Officer

 

5

 

 

 EX-99.1 2 tm2317787d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

AMEDISYS ANNOUNCES RECEIPT OF UNSOLICITED PROPOSAL FROM OPTUM

 

Amedisys Board Determines Optum Proposal Could Reasonably be Expected

to Result in a Superior Proposal

 

Amedisys Engaging in Discussions with Optum

 

BATON ROUGE, La., June 5, 2023 – Amedisys, Inc. (“Amedisys” or the “Company”) (NASDAQ: AMED) today announced that on May 26, 2023, the Company received an unsolicited proposal from Optum, a diversified health services company, to acquire all of the outstanding shares of Amedisys’ common stock in an all-cash transaction for $100 per share.

 

As announced on May 3, 2023, Amedisys entered into a merger agreement with Option Care Health, Inc. (“Option Care Health”) (NASDAQ: OPCH), under which Amedisys and Option Care Health would combine in an all-stock transaction. Under the terms of the merger agreement, Amedisys stockholders would receive 3.0213 shares of Option Care Health common stock for each existing share of Amedisys common stock they hold at the closing of the transaction. Upon closing Amedisys stockholders are expected to own approximately 35.5% of the outstanding shares of the combined company on a fully diluted basis. The transaction is subject to approval by Option Care Health stockholders and Amedisys stockholders, receipt of applicable regulatory approvals, including termination or expiration of the applicable waiting periods under the HSR Act and state insurance approvals, and other customary closing conditions.

 

Consistent with its fiduciary duties, the Amedisys Board of Directors (the “Board”) consulted with its outside counsel and financial advisor to thoroughly evaluate Optum’s proposal. The Board conducted this evaluation in accordance with the terms of the Company’s merger agreement with Option Care Health.

 

On May 27, 2023, the Board determined that the unsolicited proposal received from Optum could reasonably be expected to result in an “Amedisys Superior Proposal” as defined in Amedisys’ merger agreement with Option Care Health. As permitted by the terms of Amedisys’ merger agreement with Option Care Health, Amedisys entered into a confidentiality agreement with Optum on May 30, 2023 and is currently engaging in exploratory discussions with Optum with respect to Optum’s proposal.

 

Amedisys remains bound by the terms of the merger agreement with Option Care Health, and Amedisys’ Board has not determined that Optum’s proposal constitutes a Superior Proposal as defined in the merger agreement with Option Care Health. The merger agreement with Option Care Health does not permit Amedisys to terminate the merger agreement in favor of an alternative transaction, or to enter into any agreements with respect to an alternative transaction, other than a confidentiality agreement. Amedisys notes that there can be no assurance that the discussions with Optum will result in a transaction.

 

Amedisys stockholders do not need to take any action at this time. The Amedisys Board’s recommendation in favor of the merger agreement with Option Care Health and the merger with Option Care Health continues to be in effect.

 

1

 

No Offer or Solicitation

 

This communication relates to the proposed merger (the “proposed transaction”) between Option Care Health and Amedisys. This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

 

Additional Information and Where to Find It

 

In connection with the proposed transaction, Option Care Health and Amedisys have filed relevant materials with the United States Securities and Exchange Commission (the "SEC"), including an Option Care Health registration statement on Form S-4 that includes a preliminary joint proxy statement of Option Care Health and Amedisys that also constitutes a prospectus of Option Care Health. The registration statement has not been declared effective by the SEC. A definitive joint proxy statement/prospectus will be mailed to stockholders of Option Care Health and Amedisys after the registration statement has been declared effective by the SEC. INVESTORS AND SECURITY HOLDERS OF OPTION CARE HEALTH AND AMEDISYS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS THAT HAVE BEEN OR WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders may obtain free copies of the registration statement and the joint proxy statement/prospectus and other documents filed with the SEC by Option Care Health or Amedisys through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by Option Care Health are available free of charge on Option Care Health's internet website at https://investors.optioncarehealth.com or by contacting Option Care Health's investor relations department at investor.relations@optioncare.com. Copies of the documents filed with the SEC by Amedisys are available free of charge on Amedisys' internet website at https://investors.amedisys.com or by contacting Amedisys' investor relations department at IR@amedisys.com.

 

Certain Information Regarding Participants

 

Option Care Health, Amedisys and their respective directors and executive officers may be considered participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of Option Care Health is set forth in its proxy statement for its 2023 annual meeting of stockholders, which was filed with the SEC on April 7, 2023. Information about the directors and executive officers of Amedisys is set forth in its proxy statement for its 2023 annual meeting of stockholders, which was filed with the SEC on April 27, 2023. Other information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, is contained in the joint proxy statement/prospectus and other relevant materials filed with the SEC regarding the proposed transaction. You may obtain these documents free of charge through the website maintained by the SEC at http://www.sec.gov and from the investor relations departments at Option Care Health or Amedisys as described above.

 

2

 

Cautionary Statement Regarding Forward-Looking Statements

 

This communication may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include projections as to the anticipated benefits of the proposed transaction as well as statements regarding the impact of the proposed transaction on Option Care Health’s and Amedisys’ business and future financial and operating results, the amount and timing of synergies from the proposed transaction and the closing date for the proposed transaction.

 

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management's current beliefs, expectations and assumptions regarding the future of Option Care Health’s and Amedisys’ business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Option Care Health’s and Amedisys’ control. Option Care Health’s, Amedisys’ and the combined company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements as a result of various factors. These factors include, among other things, (1) the termination of or occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement or the inability to complete the proposed transaction on the anticipated terms and timetable, (2) the inability to complete the proposed transaction due to the failure to obtain approval of the stockholders of Option Care Health or Amedisys or to satisfy any other condition to closing in a timely manner or at all, or the risk that a regulatory approval that may be required for the proposed transaction is delayed, is not obtained or is obtained subject to conditions that are not anticipated, (3) the ability to recognize the anticipated benefits of the proposed transaction, which may be affected by, among other things, the ability of the combined company to maintain relationships with its patients, payers and providers and retain its management and key employees, (4) the ability of the combined company to achieve the synergies contemplated by the proposed transaction or such synergies taking longer to realize than expected, (5) costs related to the proposed transaction, (6) the ability of the combined company to execute successfully its strategic plans, (7) the ability of the combined company to promptly and effectively integrate the Option Care Health and Amedisys businesses and (8) the diversion of management's time and attention from ordinary course business operations to completion of the proposed transaction and integration matters. The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included elsewhere. Additional information concerning risks, uncertainties and assumptions can be found in Option Care Health’s and Amedisys’ respective filings with the SEC, including the risk factors discussed in Option Care Health’s and Amedisys’ most recent Annual Reports on Form 10-K, as updated by their Quarterly Reports on Form 10-Q and future filings with the SEC, as well as the risk factors set forth in the joint proxy statement/prospectus.

 

Any forward-looking statement made in this communication is based only on information currently available to Option Care Health and Amedisys and speaks only as of the date on which it is made. Option Care Health and Amedisys undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. You are cautioned not to rely on Option Care Health’s and Amedisys’ forward-looking statements.

 

3

 

About Amedisys

 

Amedisys, Inc. is a leading healthcare at home company delivering personalized home health, hospice and high-acuity care services. Amedisys is focused on delivering the care that is best for our patients, whether that is inpatient hospital, palliative, and skilled nursing facility (“SNF”) care in their homes; home-based recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 3,000 hospitals and 102,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 18,000 employees in 522 care centers in 37 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 455,000 patients in need every year, performing more than 11.2 million visits annually. For more information about the Company, please visit: www.amedisys.com.

 

AMEDISYS CONTACT

Nick Muscato

Chief Strategy Officer

(855) 259-2046

IR@amedisys.com

 

MEDIA CONTACT

Andrew Cole / Emily Claffey / Bridget Nagle

FGS Global

(212) 687- 8080

Amedisys@fgsglobal.com

 

4

 

 EX-101.SCH 3 amed-20230605.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 amed-20230605_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 amed-20230605_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2317787d1_8kimg001.jpg GRAPHIC begin 644 tm2317787d1_8kimg001.jpg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htm IDEA: XBRL DOCUMENT v3.23.1
Cover
Jun. 05, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 05, 2023
Entity File Number 0-24260
Entity Registrant Name Amedisys, Inc.
Entity Central Index Key 0000896262
Entity Tax Identification Number 11-3131700
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 3854 American Way
Entity Address, Address Line Two Suite A
Entity Address, City or Town Baton Rouge
Entity Address, State or Province LA
Entity Address, Postal Zip Code 70816
City Area Code 225
Local Phone Number 292-2031
Written Communications true
Soliciting Material true
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock. $0.001 par value per share
Trading Symbol AMED
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm2317787d1_8k_htm.xml IDEA: XBRL DOCUMENT 0000896262 2023-06-05 2023-06-05 iso4217:USD shares iso4217:USD shares 0000896262 false 8-K 2023-06-05 0-24260 Amedisys, Inc. DE 11-3131700 3854 American Way Suite A Baton Rouge LA 70816 225 292-2031 true true false false Common Stock. $0.001 par value per share AMED NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://amedisys.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2317787d1_8k.htm amed-20230605.xsd amed-20230605_lab.xml amed-20230605_pre.xml tm2317787d1_ex99-1.htm tm2317787d1_8kimg001.jpg http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2317787d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm2317787d1_8k.htm" ] }, "labelLink": { "local": [ "amed-20230605_lab.xml" ] }, "presentationLink": { "local": [ "amed-20230605_pre.xml" ] }, "schema": { "local": [ "amed-20230605.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "AMED", "nsuri": "http://amedisys.com/20230605", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "tm2317787d1_8k.htm", "contextRef": "From2023-06-05to2023-06-05", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://amedisys.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "tm2317787d1_8k.htm", "contextRef": "From2023-06-05to2023-06-05", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amedisys.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001104659-23-068102-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-068102-xbrl.zip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